Alvotech（ALVO）管理层披露了对2026财年的业绩展望。根据最新预测，公司预计全年总营收将落在6.5亿至7亿美元区间，同时调整后EBITDA有望达到1.8亿至2.2亿美元的水平。
这一预期反映了管理层对生物类似药市场需求的积极判断，以及在成本管控和生产效率提升方面所取得的进展。该公司在公告中同时给出了两项核心财务指标的指引范围，显示出其对未来经营走势的明确态度。
从营收端来看，这一指引区间较往年有显著提升，表明Alvotech正加快其产品管线的商业化步伐。而在盈利能力方面，调整后EBITDA的正向区间预期，则暗示着公司运营杠杆效应正逐步显现。管理层此番表态，为市场提供了清晰的业绩参照框架。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.